4DMT Partners with Otsuka for Revolutionary Eye Disease Treatment in Asia-Pacific

4D Molecular Therapeutics secures $85M upfront deal with Otsuka Pharmaceutical to bring 4D-150, a potential one-time eye injection treatment, to Asia-Pacific markets.